In addition to the global #1 ranking in biosimilars1 and generic antibiotics2, dermatology2 and transplantation medicines2, Sandoz portfolio of products in Canada includes six biosimilars and over 700 generic products3 covering 280 molecules and medicinal ingredients spanning multiple therapeutic areas including:
Central nervous system (CNS)
Our broad portfolio encompasses a range of formulations and devices, including injectables, multiple-unit tablets, capsules, creams and gels, transdermal patches, and lyophilized products.
Our medicines are sold in pharmacies and used in hospitals. In 2019, Sandoz was the main provider of generic injectable medications4 to Canadian hospitals.
We are proud to play an essential role in the Canadian health care system. In 2019, Sandoz products were prescribed over 65 million times5 in Canada.
A trusted partner of healthcare professionals, Sandoz Canada has a network of suppliers that stand out for their reliability and high-quality standards. Our dedicated sales force is distinguished by the strong business relationships it has with customers and the excellent service it provides. Our broad product line falls into two categories: Generic medicines and Biosimilars.
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2019, our products reached well over 500 million patients worldwide. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. For more information about Sandoz International, visit https://www.sandoz.com/